Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: Making better use of C-reactive protein to deliver individualized therapy

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 11, 2016, Pages 3168-3178

  Ramos Martin V ^a,b   Neely, M N ^c   McGowan, P ^d   Siner, S ^b   Padmore, K ^b   Peak, M ^b   Beresford, M W ^a,b   Turner, M A ^a,d   Paulus, S ^b   Hope, W W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d LIVERPOOL WOMEN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CIPROFLOXACIN; GENTAMICIN; TEICOPLANIN; ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; HUMAN; MATHEMATICAL MODEL; MONTE CARLO METHOD; NEWBORN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; STEADY STATE; CLINICAL TRIAL; FEMALE; INFANT; MALE;

ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MONTE CARLO METHOD; TEICOPLANIN;

EID: 84994496293     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw295     Document Type: Article

References (38)

1. Stoll BJ, Hansen N, Fanaroff AA et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110: 285-91.
2. Marchant EA, Boyce GK, Sadarangani M et al. Neonatal sepsis due to coagulase-negative staphylococci. Clin Dev Immunol 2013; 2013: 586076.
3. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 2006; 19: 290-7.
4. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic reviewand meta-analysis. Antimicrob Agents Chemother 2009; 53: 4069-79.
5. Cavalcanti AB, Goncalves AR, Almeida CS et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; issue 6: CD007022.
6. Ramos-Martin V, Paulus S, Siner S et al. Population pharmacokinetics of teicoplanin in children. Antimicrob Agents Chemother 2014; 58: 6920-7.
7. Philip AG, Mills PC. Use of C-reactive protein in minimizing antibiotic exposure: experience with infants initially admitted to a well-baby nursery. Pediatrics 2000; 106: E4.
8. Connell TG, Rele M, Cowley D et al. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 2007; 119: 891-6.
9. Lutsar I, Chazallon C, Carducci FIC et al. Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr 2014; 173: 997-1004.
10. Benitz WE, Han MY, Madan A et al. Serial serum C-reactive protein levels in the diagnosis of neonatal infection. Pediatrics 1998; 102: e41.
11. Ehl S, Gering B, Bartmann P et al. C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics 1997; 99: 216.
12. BMJ Group, the Royal Pharmaceutical Society of Great Britain and RPL 2014. British National Formulary for Children 2014-2015. 2014; 289-90. http://www.evidence.nhs.uk/formulary/bnfc/current/5-infections/51-antibacterial-drugs/517-some-other-antibacterials/vancomycin-andteicoplanin/vancomycin.
13. Andrews JM. Determination of Minimum Inhibitory Concentrations. 2006; 1-19. http://www.bsac.org.uk/wp-content/uploads/2012/02/Chapter-2-Determination-of-MICs-2006updated.pdf.
14. Neely MN, van Guilder MG, Yamada WM et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467-76.
15. Martini S, Prévot A, Mosig D et al. Glomerular filtration rate: measure creatinine and height rather than cystatin C! Acta Paediatr 2003; 92: 1052-7.
16. Brion LP, Fleischman AR, McCarton C et al. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth. J Pediatr 1986; 109: 698-707.
17. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104: 849-54.
18. Wurthwein G, Groll AH, Hempel G et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005; 49: 5092-8.
19. HopeWW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714-9.
20. Goutelle S, Bourguignon L, Maire PH et al. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009; 53: 2974-81.
21. Huurneman LJ, Neely M, Veringa A et al. Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy. Antimicrob Agents Chemother 2016; 60: 2336-42.
22. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_ files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf.
23. Kacet N, Dubos J, Roussel-Delvallez M. Teicoplanin and amikacin in neonates with staphylococcal infection. Pediatr Infect Dis J 1993; 12: 10.
24. Yalaz M, Cetin H, Akisu M et al. Experience with teicoplanin in the treatment of neonatal staphylococcal sepsis. J Int Med Res 32: 540-8.
25. Fanos V, Kacet N, Mosconi G. A reviewof teicoplanin in the treatment of serious neonatal infections. Eur J Pediatr 1997; 156: 423-7.
26. Wade KC, Wu D, Kaufman DA et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008; 52: 4043-9.
27. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000; 39: 167-83.
28. The electronic Medicines Compendium. Targocid 200 mg-Summary of Product Characteristics (SPC). 2014. http://www.medicines.org.uk/emc/medicine/27319/SPC.
29. Yamada T, Kubota T, Nakamura M et al. Evaluation of teicoplanin concentrations and safety analysis in neonates. Int J Antimicrob Agents 2014; 44: 458-62.
30. Matthews PC, Taylor A, Byren I et al. Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? J Infect 2007; 55: 408-13.
31. Sato M, Chida K, Suda T et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother 2006; 12: 185-9.
32. Ueda T, Takesue Y, Nakajima K et al. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration. J Infect Chemother 2012; 18: 296-302.
33. Neely MN, Youn G, Jones B et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014; 58: 309-16.
34. Bomela HN, Ballot DE, Cory BJ et al. Use of C-reactive protein to guide duration of empiric antibiotic therapy in suspected early neonatal sepsis. Pediatr Infect Dis J 2000; 19: 531-5.
35. Pourcyrous M, Bada HS, Korones SB et al. Significance of serial C-reactive protein responses in neonatal infection and other disorders. Pediatrics 1993; 92: 431-5.
36. Hedegaard SS, Wisborg K, Hvas A-M. Diagnostic utility of biomarkers for neonatal sepsis-a systematic review. Infect Dis (Lond) 2015; 47: 117-24.
37. Turner D, Hammerman C, Rudensky B et al. Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram. Arch Dis Child Fetal Neonatal Ed 2006; 91: F283-6.
38. Patil S, Dutta S, Attri SV et al. Serial C reactive protein values predict sensitivity of organisms to empirical antibiotics in neonates: a nested case-control study. Arch Dis Child Fetal Neonatal Ed 2016; doi:10.1136/archdischild-2015-309158.